{"title":"治疗相关髓系白血病的研究进展","authors":"Yimeng Niu, Yan Li","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.015","DOIUrl":null,"url":null,"abstract":"Therapy-related myeloid leukemia (TRML) is a secondary myeloid leukemia after the primary disease. It is a subtype of myeloid leukemia with high morbidity and case fatality rate. The prognosis of patients with TRML is poor, the median survival time is short, and the traditional treatment is not effective. With the deepening of the research on this disease, various new therapies, such as targeted therapy, immunotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) and other therapies have emerged constantly, which provide a new reference and research direction for the treatment of TRML. Progress on the pathogenesis, individualized diagnosis, treatment and prognosis evaluation of TRML were reviewed for clinical reference. Key words: Leukemia, myeloid; Neoplasms, second primary; Precision medicine; Molecular targeted therapy; Hematopoietic stem cell transplantation; Immunotherapy","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"41 1","pages":"539-542"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in therapy-related myeloid leukemia\",\"authors\":\"Yimeng Niu, Yan Li\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2018.06.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Therapy-related myeloid leukemia (TRML) is a secondary myeloid leukemia after the primary disease. It is a subtype of myeloid leukemia with high morbidity and case fatality rate. The prognosis of patients with TRML is poor, the median survival time is short, and the traditional treatment is not effective. With the deepening of the research on this disease, various new therapies, such as targeted therapy, immunotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) and other therapies have emerged constantly, which provide a new reference and research direction for the treatment of TRML. Progress on the pathogenesis, individualized diagnosis, treatment and prognosis evaluation of TRML were reviewed for clinical reference. Key words: Leukemia, myeloid; Neoplasms, second primary; Precision medicine; Molecular targeted therapy; Hematopoietic stem cell transplantation; Immunotherapy\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"41 1\",\"pages\":\"539-542\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Therapy-related myeloid leukemia (TRML) is a secondary myeloid leukemia after the primary disease. It is a subtype of myeloid leukemia with high morbidity and case fatality rate. The prognosis of patients with TRML is poor, the median survival time is short, and the traditional treatment is not effective. With the deepening of the research on this disease, various new therapies, such as targeted therapy, immunotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) and other therapies have emerged constantly, which provide a new reference and research direction for the treatment of TRML. Progress on the pathogenesis, individualized diagnosis, treatment and prognosis evaluation of TRML were reviewed for clinical reference. Key words: Leukemia, myeloid; Neoplasms, second primary; Precision medicine; Molecular targeted therapy; Hematopoietic stem cell transplantation; Immunotherapy
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
